Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

GREY:ATBPF - Post Discussion

View:
Post by YukonJezza on Jul 19, 2021 10:00am

Ate'$ next mission

Dan will probably sell more shares at 3.00 even. This will drop below $2.00 and Mugsy will continue to short this while praising Dan.
Comment by Amigo11 on Jul 20, 2021 6:31am
With about $1.85 in cash per share ,investors are really paying $1.40 per share for all the upside of ATE.As we didn't have any cash per share for most of our existence,a prospective investor hasnt paid this little for all the upsidd in a long time.
Comment by GameChangerBet on Jul 20, 2021 9:46am
There are essentially no positive catalysts priced in to the stock. Which means that when those events come to market, the stock will react to it fully and price it in accordingly (contrary to the typical stock market function of buy the rumor, sell the news). The data from the trials suggests a high probability of a successful outcome. Nuance agrees. Consider the amount of due diligence they have ...more  
Comment by Forestview on Jul 20, 2021 9:58am
Part of the challenge, GCB, I see is an inability to craft a proper news release that doesn't leave things ambiguous.  Right now, the only news releases are ones that include $$$ figures - retail investors understand that.  But, ATE management has not been able to translate other news releases to something that a retail investor can interpret as a good thing.  I keep going back ...more  
Comment by GameChangerBet on Jul 20, 2021 10:10am
There may be some merit to what you're saying. I think managements main focus is the business itself and the the execution of their strategy. Doesn't seem that their primary concern is the stock price or the retail investor. Personally, I'm looking past all that because I think at the end of it all, if phase 3 ends up being successful and FDA approval is granted, it would be hard to ...more  
Comment by MrMugsy on Jul 20, 2021 10:47am
I think the company knows that true value is going to come from an FDA greenlight for OTENA.  Or a partnership with Big Pharma(s) that takes risk out of the Phase 3 but brings big cash into our account.  Either way ... we can then move forward as a serious drug developer. Just like an FDA greenlight for Biogen's AD drug gave Biogen a market cap increase of $21B (since fallen due to ...more  
Comment by EfTOates28 on Jul 20, 2021 6:51pm
go home ffs. Why are you here what is the need?